CNS-focused gene therapy biotech forges manufacturing deal for hearing loss drug

05 Oct 2022
endpts.com
CollaborateGene Therapy
A growing gene therapy company is teaming up with one of the largest gene therapy manufacturers to get its drug into patients in clinical trials.
Myrtelle announced on Monday that it inked a deal with Forge Biologics to make Myr-201, a gene therapy indicated for monogenic hearing loss. The target patient population, Myrtelle said, is people with a type of hearing loss called DFNB8, or autosomal recessive deafness 8.
Forge will provide plasmid manufacturing, plus cGMP AAV process development and scaling manufacturing services at its manufacturing site in Columbus, OH, Myrtelle said in a press release. As that gets underway, Myrtelle said it plans on moving development efforts forward into Phase I/II clinical trials.
The neurological disease-focused biotech recently in-licensed the candidate in May from Rescure Hearing, a preclinical gene therapy outfit. The therapy is designed to work by delivering a copy of the TMPRSS3 gene straight into the inner ear.
Myrtelle is not the only company focused on gene therapies for hearing loss. Decibel TherapeuticsDecibel Therapeutics has been in preclinical studies for its hearing loss gene therapies while recently touting early clinical stage data for a candidate to protect against chemotherapy-induced hearing loss.
The new deal with Myrtelle comes on the heels of Forge securing a $90 million Series C round last month, bringing the total amount it’s raised so far to $330 million. Forge CEO Tim Miller told Endpoints News in September that the round only took a few months to put together as firms had already approached the gene therapy manufacturer.
Forge Biologics continues its hot streak with $90M round to boost gene therapy manufacturing services
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.